Panacea Biotec Limited has announced that the enrollment of study participants in context of DengiAll Phase-III clinical trial has been completed (i.e., 10,335 study participants).

The company shall continue to monitor each participant, post administration of the Investigational Medicinal Product (i.e., vaccine or Placebo), for a period of two years to examine the efficacy and immunogenicity of the vaccine.

DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027.